18:56:29 EST Mon 04 Nov 2024
Enter Symbol
or Name
USA
CA



Ventripoint Diagnostics Ltd (2)
Symbol VPT
Shares Issued 157,182,655
Close 2024-08-29 C$ 0.19
Market Cap C$ 29,864,704
Recent Sedar Documents

Ventripoint arranges $500,000 private placement

2024-08-29 17:45 ET - News Release

Mr. Hugh MacNaught reports

VENTRIPOINT ANNOUNCES NON-BROKERED PRIVATE PLACEMENT PURSUANT TO LISTED ISSUER FINANCING EXEMPTION

Ventripoint Diagnostics Ltd., further to its news release dated Aug. 28, 2024, intends to complete, subject to TSX Venture Exchange acceptance, a non-brokered private placement of up to $500,000 of units of the corporation at price of 19.5 cents per unit.

The offering is being made to purchasers' resident in Canada, except Quebec, pursuant to the listed issuer financing exemption under Part 5A of National Instrument 45-106, Prospectus Exempt Distributions. The securities offered under the listed issuer financing exemption will not be subject to a hold period in accordance with applicable Canadian securities laws.

There is an offering document related to the offering that can be accessed under the company's profile on SEDAR+ and on the company's website. Prospective investors should read this offering document before making an investment decision.

Each unit will consist of one common share of the corporation and one share purchase warrant of the corporation. Each warrant will entitle the holder to purchase one share at a price of 30 cents per warrant share at any time on or before the date that is six months after issuance, subject to adjustment in certain events.

The corporation may pay a cash finder's fee of up to 4 per cent of the gross proceeds of the offering. Finders may also receive common share purchase warrants equal to up to 4 per cent of the aggregate subscription amount in relation to subscribers introduced by the finders, with each finder's warrant will be exercisable into one common share at an exercise price of 19.5 cents per common share for a period of six months.

The corporation will use the proceeds of the offering to finance operational costs related sales and marketing, additional key personnel, and general working capital purposes.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (artificial intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary knowledge-based reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide the company's future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the United States, Europe and Canada.

We seek Safe Harbor.

© 2024 Canjex Publishing Ltd. All rights reserved.